ID

Methanex Reports Higher First Quarter 2024 Earnings as Methanol Prices Increase

Retrieved on: 
Wednesday, April 24, 2024
NGC, Investment, Medicine Hat, Natural gas, Plant, G3, ID, Methanex, Rare-earth element

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- For the first quarter of 2024, Methanex (TSX:MX) (NASDAQ:MEOH) reported net income attributable to Methanex shareholders of $53 million ($0.77 net income per common share on a diluted basis) compared to net income of $33 million ($0.50 net income per common share on a diluted basis) in the fourth quarter of 2023. Net income in the first quarter of 2024 was higher compared to the prior quarter primarily due to a higher average realized price and the positive impact of the mark-to-market portion of share-based compensation due to changes in Methanex's share price. Adjusted EBITDA for the first quarter of 2024 was $160 million and Adjusted net income was $44 million ($0.65 Adjusted net income per common share). This compares with Adjusted EBITDA of $148 million and Adjusted net income of $35 million ($0.52 Adjusted net income per common share) for the fourth quarter of 2023.

Key Points: 
  • Key production and operational highlights during the first quarter include:
    Geismar produced 571,000 tonnes in the first quarter of 2024 compared to 587,000 tonnes in the fourth quarter of 2023.
  • New Zealand produced 277,000 tonnes in the first quarter of 2024 compared to 344,000 tonnes in the fourth quarter of 2023.
  • Atlas produced 258,000 tonnes (Methanex interest) in the first quarter of 2024 compared to 283,000 tonnes in the fourth quarter of 2023.
  • Egypt produced 166,000 tonnes (Methanex interest - 83,000 tonnes) in the first quarter of 2024 compared to 40,000 tonnes (Methanex interest - 20,000 tonnes) in the fourth quarter of 2023.

Kaiser Aluminum Corporation Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, April 24, 2024
Table, Central Time, Treasury, Kaiser, Depreciation, News, Pacific Ocean, Security (finance), Webcast, Culture, EPS, Cost, Eastern Time Zone, Bank statement, Alloy, ID, GAAP, Growth

FRANKLIN, Tenn., April 24, 2024 (GLOBE NEWSWIRE) -- Kaiser Aluminum Corporation (NASDAQ:KALU), a leading producer of semi-fabricated specialty aluminum products serving customers worldwide with highly-engineered solutions for aerospace and high-strength, packaging, general engineering, automotive extrusions, and other industrial applications, today announced first quarter 2024 results.

Key Points: 
  • Conversion revenue for the first quarter 2024 was $367 million, reflecting a 1% decrease compared to the prior year period.
  • Adjusted net income per diluted share was $1.02 for the first quarter 2024, compared to adjusted net income per diluted share of $0.42 for the first quarter 2023.
  • Adjusted EBITDA of $62 million in the first quarter 2024 increased $16 million compared to the prior year period and increased $11 million compared to the fourth quarter 2023.
  • Kaiser Aluminum Corporation will host a conference call on Thursday, April 25, 2024, at 10:00 am (Eastern Time); 9:00 am (Central Time); 7:00 am (Pacific Time), to discuss its first quarter 2024 results.

NextNav Announces Date for First Quarter 2024 Earnings Call

Retrieved on: 
Wednesday, April 24, 2024
PNT, NN, ID, NextNav

Registration for the conference call can be completed by visiting the following website prior to, or on the day of, the conference call: https://registrations.events/direct/Q4I629362 .

Key Points: 
  • Registration for the conference call can be completed by visiting the following website prior to, or on the day of, the conference call: https://registrations.events/direct/Q4I629362 .
  • After registering, each participant will be provided with call details and a registrant ID.
  • To access the live webcast or a replay, visit the Company’s investor relations website at https://ir.nextnav.com/ .
  • A replay of the call can also be accessed via phone through May 15, 2024 by dialing (800) 770-2030 from the U.S., or (647) 362-9199 from outside the U.S.

Pixalate Releases Top 100 Connected TV (CTV) Bundle ID Rankings For Global Open Programmatic Advertising on Roku, Amazon Fire TV, Samsung Smart TV, and Apple TV in March 2024

Retrieved on: 
Wednesday, April 24, 2024
Smart TV, Advertising, LATAM, IVT, Mobile advertising, CTV, Confusion, Roku, Privacy, IDS, Amazon Fire TV, Apple TV, Channel, ID, API, Connected, Samsung

LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Pixalate , the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the March 2024 Top 100 Most Popular Bundle IDs for Open Programmatic Connected TV (CTV) Advertising.

Key Points: 
  • LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Pixalate , the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the March 2024 Top 100 Most Popular Bundle IDs for Open Programmatic Connected TV (CTV) Advertising.
  • The list includes the global top 100 most popular Bundle IDs for open programmatic advertising across the most popular CTV platforms including Roku, Amazon Fire TV, Samsung, and Apple TV.
  • The rankings are based on global open programmatic advertising data, as measured by Pixalate.
  • Pixalate’s Bundle ID to App Store ID mapping APIs can help by consistently handling Bundle IDs, ensuring accurate tracking, measurement, and reporting.

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Retrieved on: 
Wednesday, April 24, 2024
FDA, PRV, Safety, Regenerative medicine, Food, Orphan, DMD, Webcast, Biologics license application, Therapy, Priority review, Exosome, BLA, Duchenne muscular dystrophy, Marketing, ID, File, Biotechnology, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced an update from the Company’s recent Type-B Chemistry, Manufacturing and Controls (“CMC”) meeting with the U.S. Food and Drug Administration (“FDA”) on next steps for the Biologics License Application (“BLA”) submission with its lead asset CAP-1002 in treating Duchenne muscular dystrophy (“DMD”).

Key Points: 
  • The FDA has affirmed alignment with Capricor on the following topics:
    The FDA advised Capricor to include discussion for a pre-BLA meeting and rolling BLA schedule in the upcoming Type-B meeting.
  • This allows for the use of CAP-1002 drug product manufactured at our San Diego manufacturing facility upon potential product approval.
  • Data from Cohort B of the HOPE-3 clinical trial will not be necessary for FDA approval of the product.
  • Contingent upon our upcoming meeting, FDA is supportive of our plan to submit a rolling BLA, which may expedite our path to potential approval.

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Retrieved on: 
Wednesday, April 24, 2024
ID, Patient

ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.

Key Points: 
  • ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.
  • To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 1246220.
  • A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com.
  • An archived webcast will be available on the Chimerix website approximately two hours after the event.

Shoals Technologies Group, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call

Retrieved on: 
Tuesday, April 23, 2024
ID

PORTLAND, Tenn., April 23, 2024 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its first quarter 2024 results after market close on Tuesday, May 7, 2024, to be followed by a conference call at 5:00 p.m. (Eastern Time) on the same day.

Key Points: 
  • PORTLAND, Tenn., April 23, 2024 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its first quarter 2024 results after market close on Tuesday, May 7, 2024, to be followed by a conference call at 5:00 p.m. (Eastern Time) on the same day.
  • The conference call can be accessed live over the phone by dialing 1-877-407-0789 (domestic) or + 1-201-689-8562 (international).
  • A telephonic replay will be available approximately two hours after the call by dialing 1-844-512-2921 or for international callers, +1-412-317-6671.
  • The telephonic replay will be available until 11:59 p.m. Eastern Time on May 21, 2024.

Artisan Partners Asset Management Inc. Reports 1Q24 Results

Retrieved on: 
Tuesday, April 23, 2024
ID, Webcast, Eastern Time Zone

MILWAUKEE, April 23, 2024 (GLOBE NEWSWIRE) -- Artisan Partners Asset Management Inc. (NYSE: APAM) (the “Company” or “Artisan Partners”) today reported its results for the three months ended March 31, 2024, and declared a quarterly dividend.

Key Points: 
  • MILWAUKEE, April 23, 2024 (GLOBE NEWSWIRE) -- Artisan Partners Asset Management Inc. (NYSE: APAM) (the “Company” or “Artisan Partners”) today reported its results for the three months ended March 31, 2024, and declared a quarterly dividend.
  • The full March 2024 quarter earnings release and investor presentation can be viewed at www.apam.com .
  • The Company will host a conference call on April 24, 2024, at 1:00 p.m. (Eastern Time) to discuss its results for the three months ended March 31, 2024.
  • Listeners may also access the call by dialing 877.328.5507 or 412.317.5423 for international callers; the conference ID is 10187115.

First Commonwealth Announces First Quarter 2024 Earnings; Increases Quarterly Dividend

Retrieved on: 
Tuesday, April 23, 2024
Financial management, First Commonwealth Bank, Common equity, Sale, Polish–Lithuanian Commonwealth, Total, FTE, Capital, Tangibility, ACL, SBA, Bank, Acquisition, Centric, Small Business Administration, Bank statement, Hospital, PCD, ID, GAAP, Video game

The net interest margin for the first quarter of 2024 was 3.52% as compared to 3.65% in the prior quarter and 4.01% in the year ago quarter.

Key Points: 
  • The net interest margin for the first quarter of 2024 was 3.52% as compared to 3.65% in the prior quarter and 4.01% in the year ago quarter.
  • Provision for credit losses totaled $4.2 million in the first quarter of 2024 as compared to ($1.9) million in the previous quarter.
  • First Commonwealth Financial Corporation declared a common stock quarterly dividend of $0.13 per share, which represents a 4.0% increase from the previous quarter.
  • First Commonwealth will host a quarterly conference call to discuss its financial results for the first quarter of 2024 on Wednesday, April 24, 2024 at 2:00 PM (ET).

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

Retrieved on: 
Tuesday, April 23, 2024
American College, Investment, RESONANCE, Partnership, Webcast, Growth, Prescription, Patient, Patient satisfaction, ID, Pericarditis, Telephone, KNSA, Pharmaceutical industry

HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution.

Key Points: 
  • – ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –
    HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution.
  • Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023.
  • Total operating expenses for the first quarter of 2024 were $96.4 million, compared to $59.5 million for the first quarter of 2023.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 23, 2024, to discuss first quarter 2024 financial results and recent portfolio execution.